GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Chembio Diagnostics Inc (NAS:CEMI) » Definitions » Cash-to-Debt

Chembio Diagnostics (Chembio Diagnostics) Cash-to-Debt : 0.73 (As of Dec. 2022)


View and export this data going back to 2004. Start your Free Trial

What is Chembio Diagnostics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Chembio Diagnostics's cash to debt ratio for the quarter that ended in Dec. 2022 was 0.73.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Chembio Diagnostics couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2022.

The historical rank and industry rank for Chembio Diagnostics's Cash-to-Debt or its related term are showing as below:

CEMI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21   Med: 18.59   Max: No Debt
Current: 0.73

During the past 13 years, Chembio Diagnostics's highest Cash to Debt Ratio was No Debt. The lowest was 0.21. And the median was 18.59.

CEMI's Cash-to-Debt is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 1.35 vs CEMI: 0.73

Chembio Diagnostics Cash-to-Debt Historical Data

The historical data trend for Chembio Diagnostics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Chembio Diagnostics Cash-to-Debt Chart

Chembio Diagnostics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.96 0.71 0.91 1.11 0.73

Chembio Diagnostics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.11 0.95 0.88 0.82 0.73

Competitive Comparison of Chembio Diagnostics's Cash-to-Debt

For the Diagnostics & Research subindustry, Chembio Diagnostics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chembio Diagnostics's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Chembio Diagnostics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Chembio Diagnostics's Cash-to-Debt falls into.



Chembio Diagnostics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Chembio Diagnostics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Chembio Diagnostics's Cash to Debt Ratio for the quarter that ended in Dec. 2022 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chembio Diagnostics  (NAS:CEMI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Chembio Diagnostics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Chembio Diagnostics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Chembio Diagnostics (Chembio Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
3661 Horseblock Road, Medford, NY, USA, 11763
Chembio Diagnostics Inc is a company that develops, manufactures, and commercializes point-of-care diagnostic tests that detect infectious diseases. The products of the company include rapid tests for the detection of HIV 1/2 antibodies and a multiplex rapid test for the detection of HIV and syphilis antibodies. The company offered rapid medical tests that are offered in Africa, Asia, Europe, and the Middle East, Latin America and the United States, of which key revenue is derived from Latin America.
Executives
Perceptive Credit Advisors, Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Leslie Teso-lichtman director C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Charles Caso officer: See remarks C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Paul Angelico officer: See remarks C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Lawrence J. Steenvoorden officer: See remarks C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
David William Bespalko director 29 CEDAR DRIVE, ALLENDALE NJ 07401
David Acheson director C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Richard Eberly officer: See Remarks 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
John Gary Potthoff director 6140 SPANISH OAKS CLUB BLVD., AUSTIN TX 78738
Javan Esfandiari officer: Senior Vice President 3661 HORSEBLOCK ROAD, MEDFORD NY 11763
Robert Passas officer: See Remarks 3661 HORSEBLOCK ROAD, MEDFORD NY 11763
Polan Mary Lake Ph D director STANFORD UNIVERSITY SCHOOL OF MEDICINE, 300 PASTAUR DR ROOM HH333, STANFORD CA 94305-5317
Neil A Goldman officer: Executive VP and CFO 3661 HORSEBLOCK RD, MEDFORD NY 11763